---
title: "Lantern Pharma Raises $4.4 Million in Registered Direct, Adds Private Warrants; Engages Rodman and Renshaw"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286472432.md"
description: "Lantern Pharma has raised approximately $4.4 million through a registered direct offering and a concurrent private placement with institutional investors. The financing includes common shares priced at $2.06 and warrants exercisable at $2.27. The company has engaged Rodman and Renshaw as the placement agent, agreeing to a 7% cash fee and additional warrants. The funds will be used for working capital and general corporate purposes."
datetime: "2026-05-14T21:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286472432.md)
  - [en](https://longbridge.com/en/news/286472432.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286472432.md)
---

# Lantern Pharma Raises $4.4 Million in Registered Direct, Adds Private Warrants; Engages Rodman and Renshaw

Lantern Pharma completed a financing anchored by a Securities Purchase Agreement with institutional investors, raising approximately $4.4 million through a registered direct offering and issuing additional warrants in a concurrent private placement. The structure included common shares at $2.06, pre-funded warrants at $2.0599, and purchase warrants exercisable at $2.27 six months post-issuance, with a five-year life after first exercise. The company also engaged Rodman and Renshaw as sole placement agent, agreeing to a 7% cash fee, expense reimbursement, and 5% placement agent warrants. Proceeds will fund working capital and general corporate purposes.

**Agreement 1: Lantern Pharma Raises $4.4 Million in Registered Direct, Adds Private Warrants**

-   **Agreement type**: Securities Purchase Agreement for registered direct offering and concurrent private placement
-   **Counterparty**: Institutional investors
-   **Signed / Effective**: May 12 2026 / May 14 2026
-   **Duration / Termination**: Various; purchase warrants 5 years post-initial exercise
-   **Reason**: Raise capital for working capital and general corporate purposes

**Agreement 2: Lantern Pharma Taps Rodman and Renshaw as Placement Agent, Paying 7% Fee and Warrants**

-   **Agreement type**: Placement agent engagement for registered direct offering
-   **Counterparty**: Rodman and Renshaw
-   **Signed / Effective**: Apr 20 2026 / same
-   **Duration / Termination**: Through closing of offering
-   **Reason**: Secure placement services and distribution for financing

Original SEC Filing: Lantern Pharma Inc. \[ LTRN \] - 8-K - May. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LTRN.US](https://longbridge.com/en/quote/LTRN.US.md)

## Related News & Research

- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Lantern Pharma shifts LP-300 Phase 2 HARMONIC trial to single-arm L858R focus](https://longbridge.com/en/news/286903851.md)
- [Foncière 7 Investissement announces upcoming shareholder meeting](https://longbridge.com/en/news/286899752.md)
- [Hippo closes $100 million Mountain Re catastrophe bond offering](https://longbridge.com/en/news/286918075.md)
- [CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement](https://longbridge.com/en/news/286600329.md)